Acute Myeloid Leukemia (AML) Biomarker Testing Market (Type of Biomarker: Genetic, Protein, and Others; and Technology: NGS, PCR, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Feb 2023| TMR3665A| Transparency

Report Highlights

Acute Myeloid Leukemia (AML) Biomarker Testing Market – Scope of Report

TMR’s report on the global acute myeloid leukemia (AML) biomarker testing market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global acute myeloid leukemia (AML) biomarker testing market for the period 2017–2031, considering 2022 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global acute myeloid leukemia (AML) biomarker testing market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the acute myeloid leukemia (AML) biomarker testing market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global acute myeloid leukemia (AML) biomarker testing market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global acute myeloid leukemia (AML) biomarker testing market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global acute myeloid leukemia (AML) biomarker testing market.

The report delves into the competitive landscape of the global acute myeloid leukemia (AML) biomarker testing market. Key players operating in the global acute myeloid leukemia (AML) biomarker testing market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global acute myeloid leukemia (AML) biomarker testing market profiled in this report.

Key Questions Answered in Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Report

  • What is the sales/revenue generated by acute myeloid leukemia (AML) biomarker testing across all regions during the forecast period?
  • What are the opportunities in the global acute myeloid leukemia (AML) biomarker testing market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Report Synopsis

Report Metrics Details
Base year considered 2022
Forecast period considered 2022-2031
Units considered $ Million
Segments covered By Type of Biomarker, By Technology, By End Use, By Region
Industry covered Healthcare
Countries covered North America, Latin America, Europe, Asia Pacific, Middle East & Africa
Companies studied
  • Abbott Laboratories
  • NeoGenomics Laboratories
  • Bio-Rad Laboratories, Inc.
  • Genmark Saglık Urunleri
  • Laboratory Corporation of America Holdings
  • Leica Biosystems Nussloch GmbH (Danaher)
  • Medaysis Company
  • QIAGEN N.V.
  • Thermo Fisher Scientific, Inc.

Acute Myeloid Leukemia (AML) Biomarker Testing Market – Research Objectives and Research Approach

The comprehensive report on the global acute myeloid leukemia (AML) biomarker testing market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global acute myeloid leukemia (AML) biomarker testing market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global acute myeloid leukemia (AML) biomarker testing market.

  • Table 1 : Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by Type of Biomarker, 2017–2031
  • Table 2 : Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by Technology, 2017–2031
  • Table 3 : Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by End-use, 2017–2031
  • Table 4 : Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by Region, 2017–2031
  • Table 5 : North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by Country, 2017–2031
  • Table 6 : North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by Type of Biomarker, 2017–2031
  • Table 7 : North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by Technology, 2017–2031
  • Table 8 : North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by End-use, 2017–2031
  • Table 9 : Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by Type of Biomarker, 2017–2031
  • Table 10 : Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by Type of Biomarker, 2017–2031
  • Table 11 : Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by Technology, 2017–2031
  • Table 12 : Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by End-use, 2017–2031
  • Table 13 : Asia Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by Type of Biomarker, 2017–2031
  • Table 14 : Asia Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by Type of Biomarker, 2017–2031
  • Table 15 : Asia Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by Technology, 2017–2031
  • Table 16 : Asia Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by End-use, 2017–2031
  • Table 17 : Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
  • Table 18 : Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by Type of Biomarker, 2017–2031
  • Table 19 : Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by Technology, 2017–2031
  • Table 20 : Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by End-use, 2017–2031
  • Table 21 : Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
  • Table 22 : Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by Type of Biomarker, 2017–2031
  • Table 23 : Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by Technology, 2017–2031
  • Table 24 : Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, by End-use, 2017–2031
  • Figure 1 : Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, 2017–2031
  • Figure 2 : Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by Type of Biomarker, 2021 and 2031
  • Figure 3 : Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by Type of Biomarker, 2022–2031
  • Figure 4 : Global Acute Myeloid Leukemia (AML) Biomarker Testing Market (US$ Mn), by Genetic, 2017–2031
  • Figure 5 : Global Acute Myeloid Leukemia (AML) Biomarker Testing Market (US$ Mn), by Protein, 2017-2031
  • Figure 6 : Global Acute Myeloid Leukemia (AML) Biomarker Testing Market (US$ Mn), by Others, 2017-2031
  • Figure 7 : Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by Technology, 2021 and 2031
  • Figure 8 : Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by Technology, 2022–2031
  • Figure 9 : Global Acute Myeloid Leukemia (AML) Biomarker Testing Market (US$ Mn), by NGS, 2017–2031
  • Figure 10 : Global Acute Myeloid Leukemia (AML) Biomarker Testing Market (US$ Mn), by PCR, 2017-2031
  • Figure 11 : Global Acute Myeloid Leukemia (AML) Biomarker Testing Market (US$ Mn), by Others, 2017-2031
  • Figure 12 : Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by End-use, 2021 and 2031
  • Figure 13 : Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by End-use, 2022–2031
  • Figure 14 : Global Acute Myeloid Leukemia (AML) Biomarker Testing Market (US$ Mn), by Research Use Only, 2017–2031
  • Figure 15 : Global Acute Myeloid Leukemia (AML) Biomarker Testing Market (US$ Mn), by In Vitro Diagnostic Use, 2017-2031
  • Figure 16 : Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by Region, 2021 and 2031
  • Figure 17 : Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by Region, 2022–2031
  • Figure 18 : North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, 2017–2031
  • Figure 19 : North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by Country, 2021 and 2031
  • Figure 20 : North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by Country, 2022–2031
  • Figure 21 : North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by Type of Biomarker, 2021 and 2031
  • Figure 22 : North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by Type of Biomarker, 2022–2031
  • Figure 23 : North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by Technology, 2021 and 2031
  • Figure 24 : North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by Technology, 2022–2031
  • Figure 25 : North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by End-use, 2021 and 2031
  • Figure 26 : North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by End-use, 2022–2031
  • Figure 27 : Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, 2017–2031
  • Figure 28 : Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
  • Figure 29 : Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
  • Figure 30 : Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by Type of Biomarker, 2021 and 2031
  • Figure 31 : Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by Type of Biomarker, 2022–2031
  • Figure 32 : Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by Technology, 2021 and 2031
  • Figure 33 : Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by Technology, 2022–2031
  • Figure 34 : Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by End-use, 2021 and 2031
  • Figure 35 : Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by End-use, 2022–2031
  • Figure 36 : Asia Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, 2017–2031
  • Figure 37 : Asia Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
  • Figure 38 : Asia Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
  • Figure 39 : Asia Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by Type of Biomarker, 2021 and 2031
  • Figure 40 : Asia Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by Type of Biomarker, 2022–2031
  • Figure 41 : Asia Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by Technology, 2021 and 2031
  • Figure 42 : Asia Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by Technology, 2022–2031
  • Figure 43 : Asia Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by End-use, 2021 and 2031
  • Figure 44 : Asia Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by End-use, 2022–2031
  • Figure 45 : Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, 2017–2031
  • Figure 46 : Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
  • Figure 47 : Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
  • Figure 48 : Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by Type of Biomarker, 2021 and 2031
  • Figure 49 : Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by Type of Biomarker, 2022–2031
  • Figure 50 : Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by Technology, 2021 and 2031
  • Figure 51 : Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by Technology, 2022–2031
  • Figure 52 : Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by End-use, 2021 and 2031
  • Figure 53 : Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by End-use, 2022–2031
  • Figure 54 : Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (US$ Mn) Forecast, 2017–2031
  • Figure 55 : Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
  • Figure 56 : Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
  • Figure 57 : Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by Type of Biomarker, 2021 and 2031
  • Figure 58 : Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by Type of Biomarker, 2022–2031
  • Figure 59 : Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by Technology, 2021 and 2031
  • Figure 60 : Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by Technology, 2022–2031
  • Figure 61 : Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Analysis and Forecast, by End-use, 2021 and 2031
  • Figure 62 : Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Attractiveness Analysis, by End-use, 2022–2031

Leaders in analytics, research and advisory services for Fortune 500 companies, scores of high potential startups, and financial institutions. Our success stories have proven why we are a prominent provider of a cutting-edge syndicated and customized research services. Leverage the best of our seasoned research analysts who had a keen interest and enviable expertise of almost 4 million hours in global, regional, and local market intelligence.

Transparency
Price: $5795

Become a Member

Already a member? Login here.

Have a Question? Ask Us.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
Custom Research

Need a custom data table, graph or complete report? Tell us more.

RELATED REPORTS